4997
NIHON NOHYAKU CO.,LTD.
日本農薬
- Industry
- Chemicals
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2021
71,525
Mar 2022
81,910
Mar 2023
102,090
Mar 2024
103,033
Mar 2025
99,966
Operating profit(million JPY)
Mar 2021
6,981
Mar 2022
6,642
Mar 2023
8,739
Mar 2024
7,438
Mar 2025
8,576
Operating profit margin(%)
Mar 2021
9.76
Mar 2022
8.11
Mar 2023
8.56
Mar 2024
7.22
Mar 2025
8.58
Profit before tax(million JPY)
Mar 2021
5,850
Mar 2022
5,818
Mar 2023
7,738
Mar 2024
5,858
Mar 2025
4,556
Profit(million JPY)
Mar 2021
4,344
Mar 2022
4,502
Mar 2023
4,488
Mar 2024
4,777
Mar 2025
2,356
Total assets(million JPY)
Mar 2021
107,969
Mar 2022
118,247
Mar 2023
136,652
Mar 2024
157,983
Mar 2025
152,216
Cash and cash equivalents(million JPY)
Mar 2021
17,414
Mar 2022
11,061
Mar 2023
14,366
Mar 2024
19,264
Mar 2025
22,219
Cash flows from operating activities(million JPY)
Mar 2021
5,776
Mar 2022
-3,080
Mar 2023
-1,923
Mar 2024
-344
Mar 2025
10,405
Cash flows from investing activities(million JPY)
Mar 2021
-283
Mar 2022
-706
Mar 2023
-1,338
Mar 2024
-4,808
Mar 2025
-354
Cash flows from financing activities(million JPY)
Mar 2021
-197
Mar 2022
-2,558
Mar 2023
6,171
Mar 2024
9,835
Mar 2025
-6,940
Return on equity(%)
Mar 2021
7.4
Mar 2022
7.12
Mar 2023
6.58
Mar 2024
6.41
Mar 2025
3.03
Equity ratio(%)
Mar 2021
56.43
Mar 2022
55.47
Mar 2023
51.89
Mar 2024
49.42
Mar 2025
50.78
Earnings per share(JPY per share)
Mar 2021
55.23
Mar 2022
57.32
Mar 2023
57.23
Mar 2024
60.89
Mar 2025
30.06
Net assets per share(JPY per share)
Mar 2021
774.76
Mar 2022
836.39
Mar 2023
904.26
Mar 2024
994.96
Mar 2025
987.63
Dividend per share(JPY per share)
Mar 2021
15
Mar 2022
15
Mar 2023
16
Mar 2024
18
Mar 2025
22
Payout ratio(%)
Mar 2021
27.16
Mar 2022
26.17
Mar 2023
27.96
Mar 2024
29.56
Mar 2025
73.19
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.